Earnings Call Insights: Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Christophe Weber, CEO, announced his ...

Takeda's positive developments and shareholder-friendly measures justify a moderate "Buy" rating for conservative long-term investors. In the Q3 2024 earnings call, Takeda’s Chief Financial ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited ... to Insider Monkey’s database of 900 as of Q3 2024. Why are we interested in the stocks that ...

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...

Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin ...

Japan's Takeda has secured its first regulatory approval – in Indonesia – for its dengue fever vaccine TAK-003, which has been tipped as a potential blockbuster product.

NICE recommended Pfizer's Adcetris for NHS use in advanced Hodgkin lymphoma, citing strong trial data and a new discount agreement with Takeda. Vandana Singh Chinese Biotech Ascentage Pharma's ...